Global Injectable Drug Delivery Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	June, 2023	DTAM18020146

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	June, 2023
SKU	DTAM18020146

Global Injectable Drug Delivery Market - 2023-2030

The Global Injectable Drug Delivery Market reached USD 607.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1,364.1 billion by 2030. The injectable drug delivery market is expected to exhibit a cagr of 10.9% during the forecast period 2023-2030.

Continuous innovations are subjected to improve patients’ experience during injectable drug delivery with the help of certain reminders, the self-use of devices, connectivity of smartphones, and others. Moreover, the current self-injection devices, including pen and needle-free injectors, have made injectable drug delivery comparatively easier.

An injectable is any medication dispensed into the body via injections. The increasing number of injectable product development and approvals, among other factors, are driving the growth of the Global Injectable Drug Delivery Market during the forecast period.

Market Dynamics

The Increasing Number of Market Developments is Driving the Global Injectable Drug Delivery Market Growth in the Forecast Period

The increasing market developments, such as product introductions, product approvals, acquisitions, collaborations, mergers, expansion, and investments, among others, are driving the growth of the global injectable drug delivery market during the forecast period.

For instance, in February 2022, Takeda, a Japanese multinational pharmaceutical corporation, acquired US FDA authorization for its TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) utilized to avert episodes of hereditary angioedema (HAE) in adult and pediatric patients (12 years and above).

The Growing Geriatric Population is Providing the Global Injectable Drug Delivery Market with Prospective Growth Opportunities

Parenteral drug delivery is vastly utilized for geriatrics to attain and sustain a therapeutic concentration of medications with a narrow therapeutic index or poor oral bioavailability. Thus, the growing geriatric population presents the global market with future growth opportunities in the upcoming years.

For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

The Russia-Ukraine war has had a negative influence on the market since the Russian invasion of Ukraine with 292 attacks has damaged or destroyed 218 hospitals and clinics, over 65 attacks on ambulances, and 181 attacks on other health infrastructure, like blood centers, dental clinics, and pharmacies.

Global Recession Impact Analysis

All over the globe, climbing inflation is considerably impacting the Global Injectable Drug Delivery Market. Most pharmaceutical corporations are observing elevated prices for raw materials and are anticipating a reduction in profit margins.

The healthcare market is significantly controlled when it arrives to the pricing of generic and prescription medicines. Nevertheless, pharma corporations are encountering growing stress on drug pricing. The primary cause for this growing pricing strain is the elevated rate of inflation negatively impacting global market growth.

Artificial Intelligence Impact Analysis

Artificial intelligence is having a positive impact on the global injectable drug delivery market owing to increasing product developments. For instance, a group of investigators has harnessed Google`s AI venture DeepMind to design a bacterial injection system that can inject proteins, such as cancer-killing medicines and gene treatments, directly into human cells.

Segment Analysis

The Global Injectable Drug Delivery Market is segmented based on product type, packaging, therapeutic application, route of administration, distribution channel, and region.

The Hormonal Therapeutic Application Segment is Estimated to Hold highest Share of the Global Market.

Owing to the increasing product approvals for hormonal disorders and growing cases of hormonal disorders the hormonal therapeutic application segment is estimated to hold 30.9% of the global injectable drug delivery market.

For instance, in July 2022, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a favorable view and suggested consent for the usage of Mounjaro (tirzepatide) auto-injector pen for type 2 diabetes. Moreover, the 2022 National Diabetes Statistics Report by CDC estimated that over 130 million adults with diabetes or prediabetes in the United States.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Injectable Drug Delivery Market During the Forecast Period

Owing to the increasing product approvals in Europe, the region is estimated to be around 29.6% of the global injectable drug delivery market by 2030.

For instance, in February 2021, Xeris Pharmaceuticals acquired authorization from the European Commission (EC) for its Ogluo (glucagon) pre-filled pen indicated for treating extreme hypoglycemia in children, adults, and adolescents aged 2 years and over with diabetes mellitus.

Competitive Landscape

The major global players in the market include Becton Dickinson & Company, Baxter International, Inc., Gerresheimer AG, Pfizer, Inc., Schott AG, Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceutical Industries Ltd, Corning Incorporated, among others.

Why Purchase the Report?
• To visualize the Global Injectable Drug Delivery Market segmentation based on product type, packaging, therapeutic application, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous injectable drug delivery market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Injectable Drug Delivery Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Product Type; 3.2. Snippet by Packaging; 3.3. Snippet by Therapeutic Application; 3.4. Snippet by Route of Administration; 3.5. Snippet by Distribution Channel; 3.6. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Product Advancements; 4.1.1.2. Market Developments; 4.1.2. Restraints; 4.1.2.1. Needle Stick injuries; 4.1.2.2. The Increasing Use of Alternative Drug Delivery Systems; 4.1.3. Opportunity; 4.1.4. Government Initiatives; 4.1.5. Impact Analysis
5. Industry Analysis: 5.1. Porter's 5 Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID-19; 6.1.2. Scenario During COVID-19; 6.1.3. Post COVID-19 & Future Scenario; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturers’ Strategic Initiatives; 6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Product Type: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 10.1.2. Market Attractiveness Index, By Product Type; 10.2. Devices; 10.2.1. Introduction; 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 10.2.3. Conventional injection devices; 10.2.4. Self-injection devices; 10.2.5. Autoinjectors; 10.2.6. Pen Injectors; 10.2.7. Wearable injectors; 10.2.8. Other devices; 10.3. Formulations; 10.3.1. Conventional drug delivery formulation; 10.3.1.1. Solutions; 10.3.1.2. Reconstituted/Lyophilized Formulations; 10.3.1.3. Suspensions; 10.3.1.4. Emulsions; 10.3.2. Novel drug formulations; 10.3.2.1. Niosomes; 10.3.2.2. Liposomes; 10.3.2.3. Polymeric/mixed cells; 10.3.2.4. Microparticles
11. By Packaging: 11.1. Introduction; 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging; 11.1.2. Market Attractiveness Index, By Packaging; 11.2. Vials*; 11.2.1. Introduction; 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 11.3. Ampule; 11.4. Bottle; 11.5. Cartridges; 11.6. Others
12. By Therapeutic Application: 12.1. Introduction; 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application; 12.1.2. Market Attractiveness Index, By Therapeutic Application; 12.2. Autoimmune Disease; 12.2.1. Introduction; 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 12.3. Hormonal Disorders; 12.4. Orphan disease; 12.5. Cancer; 12.6. Other therapeutic diseases
13. By Route of Administration: 13.1. Introduction; 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 13.1.2. Market Attractiveness Index, By Route of Administration; 13.2. Intradermal; 13.2.1. Introduction; 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 13.3. Central Nervous System; 13.4. Others
14. By Distribution Channel: 14.1. Introduction; 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 14.1.2. Market Attractiveness Index, By Distribution Channel; 14.2. Online Pharmacies; 14.2.1. Introduction; 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 14.3. Retail pharmacies; 14.4. Hospital Pharmacies; 14.5. Others
15. By Region: 15.1. Introduction; 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 15.1.2. Market Attractiveness Index, By Region; 15.2. North America; 15.2.1. Introduction; 15.2.2. Key Region-Specific Dynamics; 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging; 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application; 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 15.2.8.1. The U.S.; 15.2.8.2. Canada; 15.2.8.3. Mexico; 15.3. Europe; 15.3.1. Introduction; 15.3.2. Key Region-Specific Dynamics; 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging; 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application; 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 15.3.8.1. Germany; 15.3.8.2. The U.K.; 15.3.8.3. France; 15.3.8.4. Italy; 15.3.8.5. Russia; 15.3.8.6. Rest of Europe; 15.4. South America; 15.4.1. Introduction; 15.4.2. Key Region-Specific Dynamics; 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging; 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application; 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 15.4.8.1. Brazil; 15.4.8.2. Argentina; 15.4.8.3. Rest of South America; 15.5. Asia-Pacific; 15.5.1. Introduction; 15.5.2. Key Region-Specific Dynamics; 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging; 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application; 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 15.5.8.1. China; 15.5.8.2. India; 15.5.8.3. Japan; 15.5.8.4. Australia; 15.5.8.5. Rest of Asia-Pacific; 15.6. Middle East and Africa; 15.6.1. Introduction; 15.6.2. Key Region-Specific Dynamics; 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging; 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application; 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
16. Competitive Landscape: 16.1. Competitive Scenario; 16.2. Market Share Analysis; 16.3. Mergers and Acquisitions Analysis
17. Company Profiles: 17.1. Becton Dickinson & Company; 17.1.1. Company Overview; 17.1.2. Product Portfolio and Description; 17.1.3. Financial Overview; 17.1.4. Key Developments; 17.2. Baxter International, Inc.; 17.3. Gerresheimer AG; 17.4. Pfizer, Inc.; 17.5. Schott AG; 17.6. ELI Lilly and Company; 17.7. Sandoz (A Division of Novartis AG); 17.8. Terumo Corporation; 17.9. Teva Pharmaceutical Industries Ltd.; 17.10. Corning Incorporated; LIST NOT EXHAUSTIVE
18. Appendix: 18.1. About Us and Services; 18.2. Contact Us